Swiss biotech startup Reconnect Labs, founded at the University of Zurich, has secured CHF 22 million in both equity and non-dilutive funding. These resources will drive the development of AI-powered therapeutic tools and diagnostic solutions for sleep disorders, anxiety, and other mental health conditions.
Reconnect Labs operates at the clinical stage and focuses on precision neuropsychiatric therapies. By combining neuroscience, psychopharmacology, and AI, the company develops targeted molecular treatments and diagnostic instruments with the potential for long-term therapeutic impact.
Its pipeline targets conditions such as insomnia, anxiety, and substance-related disorders.
Notably, Reconnect Labs already has two candidates in Phase 2 clinical trials, underlining the maturity of its scientific development.
Unlike many conventional pharmaceutical approaches that merely alleviate symptoms, the company aims to change the actual course of mental disorders by targeting their root causes.
The integration of AI in neuropsychiatric drug development is a rare yet highly promising domain. This funding round will support Reconnect Labs’ scientific and clinical expansion while moving away from outdated paradigms.
The CHF 22 million includes both equity and non-dilutive capital, ensuring resilience and flexibility in the company’s growth.
🔗 https://reconnect-labs.com
